[go: up one dir, main page]

WO2010093191A3 - Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same - Google Patents

Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same Download PDF

Info

Publication number
WO2010093191A3
WO2010093191A3 PCT/KR2010/000893 KR2010000893W WO2010093191A3 WO 2010093191 A3 WO2010093191 A3 WO 2010093191A3 KR 2010000893 W KR2010000893 W KR 2010000893W WO 2010093191 A3 WO2010093191 A3 WO 2010093191A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
preparing
pharmaceutical composition
novel compounds
xanthine oxidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/000893
Other languages
French (fr)
Other versions
WO2010093191A2 (en
Inventor
Sung Pil Choi
Geun Tae Kim
Jeong Uk Song
Tae Hun Kim
Dong Chul Lim
Seung Wan Kang
Hyung Jin Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Chem Ltd
Original Assignee
LG Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LG Life Sciences Ltd filed Critical LG Life Sciences Ltd
Publication of WO2010093191A2 publication Critical patent/WO2010093191A2/en
Publication of WO2010093191A3 publication Critical patent/WO2010093191A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to novel compounds which are effective as an inhibitor for xanthine oxidase, a process for preparing the same, and a pharmaceutical composition comprising a therapeutically effective amount of the same.
PCT/KR2010/000893 2009-02-13 2010-02-12 Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same Ceased WO2010093191A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090011963 2009-02-13
KR10-2009-0011963 2009-02-13

Publications (2)

Publication Number Publication Date
WO2010093191A2 WO2010093191A2 (en) 2010-08-19
WO2010093191A3 true WO2010093191A3 (en) 2010-12-09

Family

ID=42562195

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/000893 Ceased WO2010093191A2 (en) 2009-02-13 2010-02-12 Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same

Country Status (2)

Country Link
KR (1) KR20100092909A (en)
WO (1) WO2010093191A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9156845B2 (en) 2012-06-29 2015-10-13 Pfizer Inc. 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011036130A1 (en) * 2009-09-24 2011-03-31 F. Hoffmann-La Roche Ag Indole derivatives as crac modulators
WO2012103436A1 (en) 2011-01-28 2012-08-02 E. I. Du Pont De Nemours And Company Method for preparing 2-aminobenzamide derivatives
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
ES2698359T3 (en) 2013-02-20 2019-02-04 Lg Chemical Ltd Sphingosine-1-phosphate receptor agonists, methods for preparing them and pharmaceutical compositions containing them as active agents
ES2807907T3 (en) 2013-08-13 2021-02-24 Natreon Inc Terminalia bellerica extract for inhibition of xanthine oxidase and decrease of uric acid in serum
ES2663622T3 (en) 2013-12-17 2018-04-16 Pfizer Inc. Novel 1-pyrrolo [2,3-b] 3,4-disubstituted pyridines and 7H-4,5-disubstituted pyridacins [2,3-c] pyridazines as inhibitors of LRRK2
JP6086105B2 (en) 2014-09-24 2017-03-01 信越半導体株式会社 Manufacturing method of SOI wafer
CN106478619B (en) * 2015-08-29 2019-09-24 江苏新元素医药科技有限公司 A kind of xanthine oxidase inhibitor and its application
ES2839201T3 (en) * 2015-09-02 2021-07-05 Sunshine Lake Pharma Co Ltd Carboxyl-substituted (hetero) aromatic ring derivatives and method of preparation and uses thereof
MX377305B (en) 2015-09-14 2025-03-07 Pfizer NOVEL IMIDAZO[4,5-c]QUINOLINE AND IMIDAZO[4,5-c][1,5]NAPHTHYRIDINE DERIVATIVES AS LRRK2 INHIBITORS.
KR102269305B1 (en) 2016-06-13 2021-06-25 길리애드 사이언시즈, 인코포레이티드 FXR (NR1H4) modulating compound
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences Inc FXR MODULATING COMPOUNDS (NR1H4)
CN110612286A (en) * 2017-02-28 2019-12-24 广东东阳光药业有限公司 Fused bicyclic derivative substituted by cyano group and its preparation method and use
PL3600309T3 (en) 2017-03-28 2022-11-07 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
HRP20240265T1 (en) 2019-01-15 2024-05-10 Gilead Sciences, Inc. Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same
CN118388473A (en) 2019-02-19 2024-07-26 吉利德科学公司 Solid forms of FXR agonists
WO2020256430A1 (en) * 2019-06-19 2020-12-24 주식회사 엘지화학 Method for producing indole or indazole compound
CN114080386B (en) * 2019-06-19 2024-05-31 株式会社Lg化学 Method for preparing indole or indazole compounds
CN111072634B (en) * 2020-01-03 2022-07-22 中国医科大学 1-substituted-3-substituted-5-substituted amide-1H-indole compound and preparation method and application thereof
WO2022233264A1 (en) * 2021-05-07 2022-11-10 江苏新元素医药科技有限公司 Class of xanthine oxidase inhibitors
CN117355513A (en) * 2021-05-21 2024-01-05 江苏恒瑞医药股份有限公司 Preparation method of BTK inhibitor intermediate
CN115925682B (en) * 2021-10-04 2025-11-25 山东新时代药业有限公司 A method for synthesizing topipusta
US20250282753A1 (en) * 2022-04-27 2025-09-11 Atom Bioscience America Corporation Compounds useful for reducing uric acid
CN116283946B (en) * 2023-03-27 2024-05-07 武汉工程大学 5- (N-substituted indole-5-yl) isoxazole-3-formic acid derivative and synthetic method and application thereof
WO2025188963A1 (en) 2024-03-06 2025-09-12 Fmc Corporation Metal catalyzed synthesis of 2-aminobenzamide derivatives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055882A1 (en) * 2001-12-24 2003-07-10 Merck Patent Gmbh Pyrrolopyrimidines as phosphodiesterase vii inhibitors
US20040034009A1 (en) * 2002-08-13 2004-02-19 Roark William Howard 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors
WO2008126898A1 (en) * 2007-04-11 2008-10-23 Kissei Pharmaceutical Co., Ltd. (aza)indole derivative and use thereof for medical purposes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055882A1 (en) * 2001-12-24 2003-07-10 Merck Patent Gmbh Pyrrolopyrimidines as phosphodiesterase vii inhibitors
US20040034009A1 (en) * 2002-08-13 2004-02-19 Roark William Howard 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors
WO2008126898A1 (en) * 2007-04-11 2008-10-23 Kissei Pharmaceutical Co., Ltd. (aza)indole derivative and use thereof for medical purposes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RACHID BENHIDA ET AL., TETRAHEDRON LETTERS, vol. 40, 1999, pages 5701 - 5703 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9156845B2 (en) 2012-06-29 2015-10-13 Pfizer Inc. 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors

Also Published As

Publication number Publication date
KR20100092909A (en) 2010-08-23
WO2010093191A2 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
WO2011043568A3 (en) Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
WO2010093191A3 (en) Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
WO2008005877A3 (en) Inhibitors of c-kit and uses thereof
MY150596A (en) Hsp90 inhibitors
EP2457908B8 (en) Process for the Preparation of Compounds useful as inhibitors of SGLT
WO2010008847A3 (en) Pi3k/m tor inhibitors
WO2011033265A8 (en) Pharmaceutical compounds
WO2009108383A3 (en) Substituted xanthine derivatives
WO2008033836A3 (en) Process and intermediates for preparing integrase inhibitors
PH12014500987A1 (en) Neprilysin inhibitors
PH12013501240A1 (en) Neprilysin inhibitors
MX354476B (en) Neprilysin inhibitors.
WO2009156179A8 (en) Her3 as a determinant for the prognosis of melanoma
WO2008075205A3 (en) Improved process for the preparation of voriconazole
WO2010098583A3 (en) Novel method for preparing statin compounds or salts thereof, and intermediate compounds used in same
WO2010015656A3 (en) Alkoxypyrazoles and the process for their preparation
WO2010006904A3 (en) Crystalline forms of rabeprazole sodium
WO2010107809A3 (en) Methods for preparing dpp-iv inhibitor compounds
WO2008089005A3 (en) Renin inhibitors
WO2011083495A3 (en) Process for the preparation of dihydroxy protected derivatives and novel intermediate compounds
WO2009007747A3 (en) Hydantoin derivatives used as mmp12 inhibitors
EP2291077A4 (en) Process for the preparation of rho-kinase inhibitor compounds
WO2010023197A3 (en) Piperidine-4-acetamide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2010111634A3 (en) Renin inhibitors
WO2009116801A3 (en) Caspase inhibitor prodrug

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10741408

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORMS 1205A DATED 03.11.2011 AND 06.12.2011)

122 Ep: pct application non-entry in european phase

Ref document number: 10741408

Country of ref document: EP

Kind code of ref document: A2